At-home Leqembi still means MRI monitoring on the same schedule as IV infusions — the subcutaneous autoinjector changes how the drug is delivered, not how closely the brain is watched. Leqembi (lecanemab) is an antibody treatment for early Alzheimer's disease, and ARIA (amyloid-related imaging abnormalities) is the brain swelling or bleeding it can cause, which is why scans stay mandatory even when the needle moves from a clinic IV line to a weekly injection at home. The FDA cleared Leqembi Iqlik as a once-weekly subcutaneous starting dose on July 13, 2026, letting newly diagnosed patients begin treatment without IV infusions (BiopharmInternational). That convenience sits on top of an MRI and ARIA safety framework the FDA tightened just a year earlier, and nothing in the new approval loosens it.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What At-Home Dosing Actually Changed
- Why the MRI Schedule Doesn't Shrink at Home
- What ARIA Is, and Who Is Most at Risk
- Making At-Home Dosing Work With the Monitoring Schedule
- Frequently Asked Questions
What At-Home Dosing Actually Changed
The at-home starting regimen is 500 mg given once a week as two 250 mg autoinjector doses, each one delivered in about 15 seconds, with a healthcare provider required to oversee at least the first two injections (BioArctic). After that supervised start, patients or caregivers can give the injections at home. This builds on an earlier approval, in August 2025, of a 360 mg weekly subcutaneous maintenance dose through the same Iqlik autoinjector — but that version was limited to patients who had already completed 18 months of IV lecanemab infusions (AJMC).
The July 2026 approval is the first version available from the very start of treatment, not just after finishing IV therapy. Patients can also switch between IV and subcutaneous dosing during the course of treatment (BiopharmInternational). What hasn't changed is who qualifies. Leqembi remains approved only for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease, and only after amyloid pathology has been confirmed through imaging or other testing — it is not approved for moderate or later-stage disease (BiopharmInternational).
Why the MRI Schedule Doesn't Shrink at Home
Public materials describing the July 2026 subcutaneous starting dose cover injection-site reactions and note overall safety comparable to IV dosing, but they do not describe any reduction in the MRI schedule. That means the same brain-imaging visits required for IV treatment still apply when the drug is given by injection at home (BioSpace, July 2026). That schedule is not light.
In August 2025, the FDA required an added monitoring MRI between the 2nd and 3rd infusion, stacked on top of scans already required before the 5th, 7th, and 14th infusions (FDA Drug Safety Communication). For a patient starting the at-home weekly injection, that means the same sequence of scheduled brain scans has to happen on the same calendar — switching to an autoinjector doesn't remove a single one of them. The reason the FDA added that extra scan is specific: of 101 serious ARIA-E cases reported to its adverse-event database, six were fatal, and most of the fatal cases clustered between the 3rd and 4th infusion rather than the 2nd-to-3rd window the new MRI targets (The Medical Letter). The added scan is meant to catch brain swelling earlier in the highest-risk stretch of treatment, before it progresses to a serious event.
What ARIA Is, and Who Is Most at Risk
ARIA stands for amyloid-related imaging abnormalities — swelling or fluid in the brain (ARIA-E) or small areas of bleeding (ARIA-H) that show up on MRI, sometimes with no symptoms at all. In the Clarity AD trial, any form of ARIA occurred in 21% of patients taking lecanemab versus 9% on placebo; ARIA-E specifically occurred in 13% of treated patients versus 2% on placebo, and 3% of treated patients had symptomatic ARIA (FDA label via Drugs.com).
One genetic factor substantially raises that risk. Leqembi's prescribing information recommends testing for the APOE ε4 gene before starting treatment, because people who carry two copies of the ε4 variant (homozygotes) have a higher rate of symptomatic and serious ARIA than those with one copy or none (FDA prescribing information). This test is done once, typically with a blood sample, before the first dose — not something an at-home injection schedule changes.
- Ask about APOE ε4 testing before starting treatment, if it hasn't been discussed already.
- Confirm the MRI schedule in writing before the first dose — before the 5th, 7th, and 14th infusions, plus the added scan between the 2nd and 3rd.
- Know that ARIA can occur without symptoms, which is why scans are scheduled regardless of how the patient feels.
- Report any new headache, confusion, vision change, nausea, or seizure to the prescribing team right away rather than waiting for the next scheduled scan.
Making At-Home Dosing Work With the Monitoring Schedule
Moving injections to home does not reduce the number of appointments a patient or caregiver needs to track — it changes which appointments are for the drug and which are for monitoring. Weekly injections can happen at home after the first two supervised doses, but MRI visits still require a trip to an imaging facility on the schedule tied to the infusion-equivalent dose count, not the calendar week.
Eisai expects the at-home starting-dose autoinjector to reach patients through specialty pharmacies by late August 2026 (BioSpace). Patients and caregivers arranging pharmacy delivery should build the MRI calendar into that planning from day one, rather than treating it as a separate track to sort out later.
- Keep a shared calendar or log that tracks dose count alongside scheduled MRI visits, since the MRI triggers are tied to dose number (2nd-3rd, 5th, 7th, 14th), not simply to elapsed weeks.
- Set reminders for MRI scheduling at least a few weeks ahead, since imaging slots can book out and a missed scan delays the next dose decision.
- Keep the prescribing clinician's contact information accessible to whoever administers the at-home injection, in case a dose needs to be paused for symptom review.
- If switching between IV and subcutaneous dosing, confirm with the care team how the switch affects the MRI count, since dose number — not route — drives the monitoring calendar (BiopharmInternational).
Frequently Asked Questions
Does the at-home injection lower the risk of ARIA compared to IV infusions?
Public materials on the subcutaneous starting dose describe overall safety as comparable to IV dosing, not reduced risk, so the same ARIA monitoring applies (BioSpace, July 2026).
Who has to give the first at-home injections?
A healthcare provider must oversee at least the first two doses before a patient or caregiver can administer the weekly injection unsupervised (BioArctic).
Can someone who already finished IV infusions switch to the at-home version?
Yes — patients may switch between IV and subcutaneous dosing during treatment, and a maintenance subcutaneous dose was already approved in August 2025 for those who completed 18 months of IV infusions (AJMC).
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: Safety and Monitoring Questions for People With Early Alzheimer’s
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: Safety and Monitoring Questions for People With Early Alzheimer’s
- Subjective Cognitive Decline Data for Public Health Action in 2026: Local Action Questions for Family Caregivers
